Compare Revvity Inc (RVTY) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Revvity Inc trades at $110.1 (market cap $11.87B), while State Street SPDR S&P Homebuilders ETF trades at $105.91. The key difference: Revvity Inc pays a 0.26% dividend while State Street SPDR S&P Homebuilders ETF pays none, and Revvity Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| RVTY | XHB | |
|---|---|---|
Market Cap | $11.87B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $117.75 | $121.36 |
52-Week Low | $82.26 | $94.86 |
Enterprise Value | $14.36B | — |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
XHB trades at $106.07, down 2.01% over the past day amid a bearish technical signal. The ETF faces mixed housing data, with June home sales declining but new legislation potentially boosting homebuilding. Technical indicators show resistance near $108 and support at $105, while oscillators remain neutral. Recent news highlights affordability challenges from high mortgage rates and record prices, yet some sentiment improvement exists.
Outlook hinges on housing market dynamics and interest rate trends. Opportunities include potential gains from the new housing law, but risks involve persistent sales weakness and economic sensitivity. Investors should weigh legislative tailwinds against macroeconomic headwinds for directional bias.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
